GSK Expands Eligible Population for Arexvy in Japan

GlaxoSmithKline (GSK) announced on May 18, 2026, that the Japanese Ministry of Health has expanded eligibility for its RSV vaccine, Arexvy, to include adults aged 18-49 at increased risk. This expansion could increase demand and market potential in Japan.

By Jeff Lewis Fri, May 29, 2026 at 8:37 AM GMT+3 2 min read · Yahoo Finance · May 29, 2026, 05:37 UTC

GSK Expands Eligible Population for Arexvy in Japan

Tickers: $GSK

Topics: pharmaceuticals RSV disease vaccines

Read the full article at Yahoo Finance

More World news

Serco Group Announces $292 Million Acquisition of QinetiQ's U.S. Business Seeking Alpha · November 12, 2026, 16:30 UTC
Ag Growth International Targets $30M in Cost Savings Amid Divergent Business Performance Seeking Alpha · November 12, 2026, 16:30 UTC
Qualstar Reports Q3 Non-GAAP EPS of $0.09 and Revenue of $2.04 Million Seeking Alpha · November 12, 2026, 16:31 UTC
Chicago Fed President Austan Goolsbee Expresses Concern Over Persistent Inflation Trends Seeking Alpha · November 12, 2026, 16:33 UTC
Nvidia CEO Jensen Huang Ousted Amid Allegations of Personal Misconduct and National Security Concerns TechCrunch · November 12, 2026, 16:32 UTC
Pomerantz Law Firm Investigates Silvercorp Metals Inc. Following Production Shortfalls and Revenue Decline PR Newswire · November 12, 2026, 16:30 UTC
Cold Spring Harbor Laboratory Raises $6.5 Million at 21st Annual Double Helix Medals Dinner PR Newswire · November 12, 2026, 16:30 UTC
Deloitte Recognized as Leader in IDC MarketScape Worldwide Digital Identity Services Assessment PR Newswire · November 12, 2026, 16:30 UTC
SpaceX Announces $74 Billion Investment in AI Data Center Projects in Texas and Arizona Seeking Alpha · November 12, 2026, 16:25 UTC
Ofcom Fines Meta £450,000 Over Inaccurate WhatsApp Business Data Seeking Alpha · November 12, 2026, 16:25 UTC